Neurofibromatosis type 1
Management of neurofibromatosis 1

Case 2: Charly (17 years old)

Charly is a 17-year-old student with neurofibromatosis type 1 (NF1). In childhood, he was closely monitored for a local diffuse plexiform neurofibroma (PN) of the left sacroiliac joint and back. He was lost to follow-up during puberty, experiencing school difficulties and frustration with frequent medical visits.

He presents again today:

  • Medical history:
    • Resection of small superficial lump at age 8
    • Focal seizures controlled on daily oxcarbazepine
  • Symptoms: severe left-sided low back and sacral pain causing significant functional limitation
  • Blood work: no abnormalities
  • MRI: diffuse PN of the lower back with infiltration of the sacroiliac joint

Mirdametinib treatment was started. Assessment summary 6 months later:

  • Stable disease
  • Severe skin toxicity with acneiform rash and paronychia (CTCAE grade 3)
  • Daily oxcarbazepine discontinued

Local/systemic skin therapy is being started to manage the skin toxicity.

Which of the following options would you choose for this patient?